ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Xianlong Chen
Matched on ORCID iD 0000-0002-3677-4281; OpenAlex author ID A5000003497. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2022: 4 papers · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper
Papers 9
- Tumor-stroma ratio combined with PD-L1 identifies pancreatic ductal adenocarcinoma patients at risk for lymph node metastases. Co-author DOI 10.1038/s41416-025-03019-z↗
- Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-024-03745-y↗
- Targeting N-glycosylation of 4F2hc mediated by glycosyltransferase B3GNT3 sensitizes ferroptosis of pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41418-023-01188-z↗
- Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal A… Co-author DOI 10.5858/arpa.2021-0471-oa↗
- The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma. First author DOI 10.7150/thno.86547↗
- PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules. First author DOI 10.1002/cjp2.259↗
- Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cjp2.260↗
- Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2022.1027459↗
- Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2022.942154↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Shuangni Yu · 9 shared papers, 2022–2025 · strength 1.97
- Paper Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma. DOI 10.1007/s00262-024-03745-y↗
- Paper Tumor-stroma ratio combined with PD-L1 identifies pancreatic ductal adenocarcinoma patients at risk for lymph node meta… DOI 10.1038/s41416-025-03019-z↗
- Paper Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Lo… DOI 10.5858/arpa.2021-0471-oa↗
- Jie Chen · 6 shared papers, 2022–2023 · strength 1.09
- Paper Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Lo… DOI 10.5858/arpa.2021-0471-oa↗
- Paper Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context i… DOI 10.3389/fimmu.2022.1027459↗
- Paper Targeting N-glycosylation of 4F2hc mediated by glycosyltransferase B3GNT3 sensitizes ferroptosis of pancreatic ductal a… DOI 10.1038/s41418-023-01188-z↗
- Yue Zhang · 3 shared papers, 2022–2023 · strength 0.53
- Paper Targeting N-glycosylation of 4F2hc mediated by glycosyltransferase B3GNT3 sensitizes ferroptosis of pancreatic ductal a… DOI 10.1038/s41418-023-01188-z↗
- Paper PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA da… DOI 10.1002/cjp2.259↗
- Paper Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma. DOI 10.1002/cjp2.260↗
- Heng Ma · 2 shared papers, 2023 · strength 0.36
- Paper The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic du… DOI 10.7150/thno.86547↗
- Paper Targeting N-glycosylation of 4F2hc mediated by glycosyltransferase B3GNT3 sensitizes ferroptosis of pancreatic ductal a… DOI 10.1038/s41418-023-01188-z↗
- Xinyuan Chen · 1 shared paper, 2024 · strength 0.36
- Xinyuan Chen · 1 shared paper, 2025 · strength 0.33
- Jie Chen · 1 shared paper, 2023 · strength 0.18
- Y. Liu · 1 shared paper, 2023 · strength 0.18
- Wei‐Min Tong · 1 shared paper, 2023 · strength 0.18
- Yue Zhang · 1 shared paper, 2022 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.